Arash Ash Alizadeh,Ronald Levy,Andrew J. Gentles,Izidore S. Lossos
申请号：
US13253491
公开号：
US20120134986A1
申请日:
2011.10.05
申请国别(地区):
US
年份:
2012
代理人:
摘要：
Measurement of a single gene expressed by tumor cells (LMO2) and a single gene expressed by the immune microenvironment (TNFRSF9), which determination may be referred to herein as a two gene score (TGS), powerfully predicts overall survival in patients with NHL, particularly overall survival in the context of anthracycline-based chemotherapy or co-treatment with anthracycline-based chemotherapy and anti-CD20 immunotherapy. It is shown herein that increased levels of LMO2 and TNFRSF9 correlate with a positive patient response and improved prognosis.
